Vol 91, No 6 (2020)
Research paper
Published online: 2020-05-05

open access

Page views 1308
Article views/downloads 924
Get Citation

Connect on Social Media

Connect on Social Media

The impact of concurrent HPV infections on the presentation of high grade cervical intraepithelial lesions

Emine Ozturk1, Onur Ince2, İbrahim Karaca1, Gokhan Demirayak1, Cihan Comba1, Ismail Alay1, Volkan Sakir Erdogan1, Suna Yıldırım Karaca3, Isa Aykut Ozdemir1
Pubmed: 32374017
Ginekol Pol 2020;91(6):324-330.


Objectives: We investigate how concurrent high-risk (hr) HPV (human papillomavirus) genotypes affect CIN2-3 risk and evaluate the relationship of different genotype combinations with cervical epithelial lesions. Material and methods: This study included HPV positive patients between the ages of 30 and 60 who underwent liquid-based cervical smears and HPV screening through community-based, cervical cancer screening programs between June 2015 and June 2017. The impact of the increase in hrHPV types was calculated by estimating how it changed the odds ratio of CIN2-3 risk. Results: The rate of multiple concurrent HPV infections was 48.7% in the CIN2-3 group and 58.4% in the CIN1 group. Among patients in the CIN2-3 and CIN1 groups, the most common HPV coinfection was respectively HPV 16+31 and HPV 16+51. The HPV 51 ratio in CIN1 patients was 28.9% and the HPV 51 ratio in the CIN2-3 patient was 6.6%. With every increase in the number of hrHPV infection types, the frequency of CIN2-3 decreased [OR: 0.72, 95% CI: 0.54-0.95]. For all hrHPV combinations, the addition of HPV 16 was associated with a higher risk of CIN2-3. Conclusions: An increase in number of hrHPV types is associated with lower CIN2-3 risk. Further cohort studies with larger samples are needed to clarify this relationship. The available evidence suggests that HPV 16 genotype plays an important role in patients with high-grade cervical lesions and has a negative impact on the cervix in concurrent multiple HPV infections.

Article available in PDF format

View PDF Download PDF file


  1. de Sanjose S, Quint WGv, Alemany L, et al. Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11): 1048–1056.
  2. Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012; 7(1): 38.
  3. Chaturvedi AK, Katki HA, Hildesheim A, et al. CVT Group. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis. 2011; 203(7): 910–920.
  4. Carozzi F, Ronco G, Gillio-Tos A, et al. New Technologies for Cervical Cancer screening (NTCC) Working Group. Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study. Eur J Cancer. 2012; 48(11): 1633–1637.
  5. Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2006; 15(7): 1274–1280.
  6. Wentzensen N, Nason M, Schiffman M, et al. New Mexico HPV Pap Registry Steering Committee. No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study. J Infect Dis. 2014; 209(6): 855–864.
  7. Darragh TM, Colgan TJ, Thomas Cox J, et al. Members of the LAST Project Work Groups, Members of LAST Project Work Groups, Members of LAST Project Work Groups. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012; 136(10): 1266–1297.
  8. Ronco G, Dillner J, Elfström KM, et al. International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014; 383(9916): 524–532.
  9. Dalstein V, Riethmuller D, Prétet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer. 2003; 106(3): 396–403.
  10. Gultekin M, Zayifoglu Karaca M, Kucukyildiz I, et al. Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women. Int J Cancer. 2018; 142(9): 1952–1958.
  11. Klug SJ, Molijn A, Schopp B, et al. Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol. 2008; 80(7): 1264–1274.
  12. Salazar KL, Zhou HS, Xu J, et al. Multiple Human Papilloma Virus Infections and Their Impact on the Development of High-Risk Cervical Lesions. Acta Cytol. 2015; 59(5): 391–398.
  13. Dickson EL, Vogel RI, Geller MA, et al. Cervical cytology and multiple type HPV infection: a study of 8182 women ages 31-65. Gynecol Oncol. 2014; 133(3): 405–408.
  14. Morrison EA, Ho GY, Vermund SH, et al. Human papillomavirus infection and other risk factors for cervical neoplasia: a case-control study. Int J Cancer. 1991; 49(1): 6–13.
  15. Fife KH, Cramer HM, Schroeder JM, et al. Detection of multiple human papillomavirus types in the lower genital tract correlates with cervical dysplasia. J Med Virol. 2001; 64(4): 550–559.
  16. Spinillo A, Gardella B, Iacobone AD, et al. Multiple human papillomavirus infection and high grade cervical intraepithelial neoplasia among women with cytological diagnosis of atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions. Gynecol Oncol. 2009; 113(1): 115–119.
  17. De Brot L, Pellegrini B, Moretti ST, et al. Infections with multiple high-risk HPV types are associated with high-grade and persistent low-grade intraepithelial lesions of the cervix. Cancer Cytopathol. 2017; 125(2): 138–143.